Concepedia

Publication | Open Access

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

DOIFull Paper Access

70

Citations

33

References

2018

Year

Andreas Schneeweiß, Tjoung‐Won Park‐Simon, Joan Albanell, Ulrik Lassen, Javier Cortés, Véronique Dièras, Marcus May, Christoph Schindler, Frederik Marmé, Juan Miguel Cejalvo,
Investigational New Drugs

Abstract

on ClinicalTrials.gov with the identifier NCT01918254 first registered on 3rd July 2013.

References

YearCitations

Page 1